Skip to main content
Psychedex

Proscaline

3,5-dimethoxy-4-propoxyphenethylamine

1Provenance card

the boundary, as counts

Sources

159 with DOI

2 strong · 9 moderate · 4 weak

Compilations

12026-05-03T11:40:10.708Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

30last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:33:50.756Z

notice · info card · emergency

Searches

202 with no results

queries and counts on the build

Claims checked

4129 supported

29 supported · 12 not

Correspondence

0received

consent field ships in Phase 4

Edges

164

derivations recorded for this entity

Complete over 15 sources, 1 compilation, and 30 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/proscaline/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-10-19issueIssued notice
  4. 2026-09-24srcChemistry and Structure-Activity Relationships of Psychedelics.
  5. 2026-09-24srcA retrospective analysis of the 'Neverending Trip' after administration of a potent full agonist of 5-HT2A receptor - 25I-NBOMe
  6. 2026-09-24srcDevelopment and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma
  7. 2026-09-24srcCorrelation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
  8. 2026-09-24srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
  9. 2026-09-24srcAcute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects
  10. 2026-09-24srcComparison of the behavioral effects of mescaline analogs using the head twitch response in mice
  11. 2026-09-24srcSerotonergic drugs and valvular heart disease
  12. 2026-09-24srcPharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
  13. 2026-09-24srcDifferential phospholipase C activation by phenylalkylamine serotonin 5-HT2A receptor agonists
  14. 2026-09-24srcC-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor
  15. 2026-09-24srcDihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives
  16. 2026-09-24srcOxycodone legal status - UK Class A/CD2, Australia Schedule 8, Canada Schedule I, US Schedule II
  17. 2026-09-24srcPiHKAL Entry #140: Proscaline (3,5-dimethoxy-4-(n)-propoxyphenethylamine)
  18. 2026-09-24srcNCATS Inxight Drugs — Proscaline (GSRS record 99G781N5IO)
  19. 2026-09-04issueIssued emergency
  20. 2026-09-04issueIssued info_card
  21. 2026-09-04issueIssued notice
  22. 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  23. 2026-06-04publicationPublication — backfill
  24. 2026-05-03revisionRevision 1
  25. 2026-05-03absenceSearched ClinicalTrials.gov for "proscaline" — no results
  26. 2026-05-03absenceSearched ClinicalTrials.gov for "proscaline" — no results
  27. 2026-05-03genGeneration — pipeline-v5pipeline-v5
  28. 2026-05-03rungeneration run

The same entries, as forms: six forms.